Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
kenitinib
- Development stage
- Unknown
- Lead developer
- Teligene
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kenitinib (also known as TSN222) is an orally bioavailable small molecule inhibitor of Bruton's tyrosine kinase (BTK) developed by Teligene. It is designed to treat various B-cell malignancies by disrupting the B-cell receptor (BCR) signaling pathway, which is essential for the growth and survival of neoplastic B cells. The drug is currently undergoing exploratory clinical evaluation in patients with relapsed or refractory B-cell lymphomas, with specific cohorts focusing on primary central nervous system lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). As a BTK inhibitor, kenitinib aims to provide a targeted therapeutic option for patients who have failed prior lines of therapy.
- Other names
- 克耐替尼kenitinib
02
Targets
P4HB (Protein disulfide-isomerase)STING (Stimulator of interferon genes protein)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on kenitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on kenitinib.